Access the recording of this exclusive session designed to translate global Alzheimer’s disease research into practical insights for Asian clinical practice.
The AD/PD™ 2026 Evidence to Asian Practice: AD Session brings together leading experts to interpret key findings from AD/PD™ 2026 and explore how they can be effectively applied across diverse healthcare settings in Asia.
About the Session
This on-demand program focuses on bridging the gap between international scientific advances and regional clinical implementation, helping clinicians integrate the latest evidence into everyday practice.
Key Objectives:
- Translate AD/PD™ 2026 insights into regionally relevant clinical strategies
- Support faster adoption of emerging therapies and diagnostics
- Encourage expert dialogue across Asia
- Provide practical guidance for improving patient outcomes
Special Focus:
Gain expert perspectives on how the latest innovations in Alzheimer’s disease can be evaluated and positioned within the Asian scientific and clinical landscape, ensuring relevance to local patient populations and healthcare systems.
Program Highlights
🔬 Moderated AD Abstract Session 1
Real-World Evidence to Assess New Therapies’ Effectiveness, Safety, and Costs
- Yuki Kujuro (Japan)
- Jin-Tai Yu (China)
🧠 Moderated AD Abstract Session 2
Early Diagnosis with Culturally Adapted Tools and Biomarkers
- Takeshi Iwatsubo (Japan)
- Kee Hyung Park (Korea)
- Jung-Lung Hsu (Taiwan)
💬 Expert Panel Discussion
A practical discussion addressing real-world challenges in implementing new evidence in Alzheimer’s care.
- Lead Discussant: Prof. Ming-Chyi Pai
- Moderator: Dr. Samuel Lockhart
Why Watch On-Demand?
- Learn from leading experts across Asia and globally
- Explore real-world data and implementation strategies
- Gain insights into emerging therapies, biomarkers, and diagnostics
- Stay at the forefront of Alzheimer’s disease management
AD/PD™ 2026 Evidence to Asian Practice is an independent medical education programme co-organized by Kenes International, the organizer of the AD/PD™ 2026 Conference, in collaboration with the Taiwan Neurological Society (TNS).
We would like to express our sincere gratitude to Prof. Rou-Shayn Chen, Chairperson of the TNS International Affairs Committee, for his valuable scientific contributions, and to EMD Asia Scientific Communication for co-organizing the programme particularly in liaising with Asian academic institutions.